Your browser is no longer supported. Please, upgrade your browser.
Ayala Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.33 Insider Own1.40% Shs Outstand12.66M Perf Week-21.81%
Market Cap166.15M Forward P/E- EPS next Y-2.18 Insider Trans-25.70% Shs Float5.62M Perf Month-1.11%
Income-24.30M PEG- EPS next Q-0.58 Inst Own30.40% Short Float0.87% Perf Quarter33.43%
Sales3.00M P/S55.38 EPS this Y-100.50% Inst Trans2.17% Short Ratio1.36 Perf Half Y33.43%
Book/sh3.71 P/B3.61 EPS next Y28.80% ROA- Target Price22.83 Perf Year-
Cash/sh3.93 P/C3.41 EPS next 5Y- ROE- 52W Range8.62 - 28.68 Perf YTD21.91%
Dividend- P/FCF- EPS past 5Y- ROI46.30% 52W High-53.24% Beta-
Dividend %- Quick Ratio8.60 Sales past 5Y- Gross Margin1.00% 52W Low55.57% ATR1.81
Employees31 Current Ratio8.60 Sales Q/Q-22.10% Oper. Margin- RSI (14)40.60 Volatility8.62% 11.11%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.22 Prev Close13.01
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume35.81K Price13.41
Recom1.80 SMA20-21.47% SMA50-7.10% SMA2006.21% Volume8,051 Change3.07%
Dec-07-20Initiated ROTH Capital Buy $20
Jun-10-20Initiated Raymond James Outperform $24
Jun-02-20Initiated Oppenheimer Outperform $23
Jun-02-20Initiated Jefferies Hold $16
Jun-02-20Initiated Citigroup Buy $25
Mar-02-21 08:00AM  
Feb-22-21 08:55AM  
Feb-19-21 10:50AM  
Feb-18-21 11:52PM  
Jan-28-21 09:15AM  
Jan-20-21 08:33AM  
Jan-13-21 04:01PM  
Jan-05-21 08:00AM  
Jan-04-21 08:00AM  
Nov-26-20 08:15PM  
Nov-17-20 08:01AM  
Nov-05-20 08:00AM  
Sep-18-20 07:00AM  
Sep-15-20 12:14PM  
Sep-14-20 08:01AM  
Sep-08-20 08:01AM  
Aug-20-20 08:01AM  
Aug-13-20 08:01AM  
Aug-10-20 09:22AM  
Jul-27-20 08:01AM  
Jun-22-20 08:00AM  
Jun-10-20 11:30AM  
Jun-01-20 08:01AM  
May-12-20 04:01PM  
May-07-20 06:58PM  
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was founded in 2017 and is based in Rehovot, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gordon Gary B.Chief Medical OfficerFeb 24Option Exercise5.163,00015,48011,520Feb 26 05:47 PM
Gordon Gary B.Chief Medical OfficerFeb 24Sale17.463,00052,3858,520Feb 26 05:47 PM
Mamluk RoniPresident & CEOFeb 24Sale17.4010,800187,919145,345Feb 24 05:42 PM
Mamluk RoniPresident & CEOFeb 23Sale17.897,126127,483156,145Feb 24 05:42 PM
Mamluk RoniPresident & CEOFeb 22Sale19.8615,200301,813163,271Feb 24 05:42 PM
Mamluk RoniPresident & CEOJan 21Sale15.041,40621,147178,471Jan 22 04:05 PM
Gordon Gary B.Chief Medical OfficerJan 20Option Exercise5.163,00015,48011,520Jan 22 04:05 PM
Mamluk RoniPresident & CEOJan 20Sale15.0319,466292,533179,877Jan 22 04:05 PM
Gordon Gary B.Chief Medical OfficerJan 20Sale15.033,00045,0848,520Jan 22 04:05 PM